Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Equity Ratio (2016 - 2025)

Northwest Biotherapeutics' Equity Ratio history spans 16 years, with the latest figure at 0.74 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.74 for Q4 2025, up 79.02% from a year ago — trailing twelve months through Dec 2025 was 0.74 (up 79.02% YoY), and the annual figure for FY2025 was 0.74, up 79.02%.
  • Equity Ratio for Q4 2025 was 0.74 at Northwest Biotherapeutics, up from 3.55 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.74 in Q4 2025 to a low of 12.16 in Q2 2021.
  • The 5-year median for Equity Ratio is 3.36 (2022), against an average of 4.15.
  • The sharpest move saw Equity Ratio tumbled 173.16% in 2021, then surged 79.02% in 2025.
  • Year by year, Equity Ratio stood at 3.09 in 2021, then crashed by 32.46% to 4.09 in 2022, then surged by 42.28% to 2.36 in 2023, then tumbled by 49.77% to 3.54 in 2024, then surged by 79.02% to 0.74 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.74, 3.55, and 3.4 for Q4 2025, Q3 2025, and Q2 2025 respectively.